fda semaglutide shortage list Hims & Hers stock falls 25% as curtails compounded GLP-1s fda not allowing compounded semaglutide
Description
Effect of sodium glucose cotransporter 2 inhibitors with low SGLT2/SGLT1 selectivity on circulating glucagon-like peptide 1 levels in type 2 diabetes mellitus
Possibly in some cases
Jul 21 2021;10(7):796-804

Efcacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: Te LixiLan-L Randomized Trial
Persistence is further affected by external factors such as cost and access

Possible advantage of glucagon-like peptide 1 receptor agonists for kidney transplant recipients with type 2 diabetes
